{"name":"Arvinas","slug":"arvinas","ticker":"ARVN","exchange":"NASDAQ","domain":"arvinas.com","description":"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for th","hq":"New Haven, CT","founded":0,"employees":"246","ceo":"John Houston","sector":"Oncology / Protein Degradation","stockPrice":11.2,"stockChange":-0.17,"stockChangePercent":-1.5,"marketCap":"$719M","metrics":{"revenue":262600000,"revenueGrowth":-84,"grossMargin":100,"rdSpend":285200000,"netIncome":-80800000,"cash":685400000,"dividendYield":0,"peRatio":-3.2,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ARV-110 patent cliff ($0.0B at risk)","drug":"ARV-110","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"ARV-471 patent cliff ($0.0B at risk)","drug":"ARV-471","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ARV-110 in Combination with Abiraterone","genericName":"ARV-110 in Combination with Abiraterone","slug":"arv-110-in-combination-with-abiraterone","indication":"Prostate cancer","status":"phase_1"},{"name":"ARV-806","genericName":"ARV-806","slug":"arv-806","indication":"Metastatic castration-resistant prostate cancer","status":"phase_1"},{"name":"ARV-110","genericName":"ARV-110","slug":"arv-110","indication":"Prostate cancer","status":"phase_1"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ARV-393","genericName":"ARV-393","slug":"arv-393","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ARV-110 in Combination with Abiraterone","genericName":"ARV-110 in Combination with Abiraterone","slug":"arv-110-in-combination-with-abiraterone","phase":"phase_1","mechanism":"Androgen receptor inhibitor","indications":["Prostate cancer"],"catalyst":""},{"name":"ARV-806","genericName":"ARV-806","slug":"arv-806","phase":"phase_1","mechanism":"ARV-806 is a PROTAC (proteolysis targeting chimera) designed to degrade the androgen receptor (AR) in prostate cancer cells.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""},{"name":"ARV-110","genericName":"ARV-110","slug":"arv-110","phase":"phase_1","mechanism":"Selective androgen receptor degrader","indications":["Prostate cancer"],"catalyst":""},{"name":"ARV-393","genericName":"ARV-393","slug":"arv-393","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Arvinas reported its fourth quarter and full year 2023 financial results, with a net loss of $143.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-18","type":"deal","headline":"Arvinas Announces Collaboration with Pfizer to Develop Protein Degradation Therapies","summary":"Arvinas entered into a collaboration with Pfizer to develop protein degradation therapies for the treatment of various diseases.","drugName":"","sentiment":"positive"},{"date":"2023-11-09","type":"trial","headline":"Arvinas Announces Positive Interim Data from Phase 1/2 Clinical Trial of ARV-110","summary":"Arvinas announced positive interim data from its Phase 1/2 clinical trial of ARV-110, a protein degradation therapy for the treatment of prostate cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9PWVJvZWpPZi1UbVZiN180OU1FTzNsc1BCTUhZSk1QNzFJcEZZSkVMTVdzakptRnFpOWVrX0hRQS1DOEtMX2ZjQThEZG1NdlRZYmVZb0k3bGlsR1hVMS1J?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN) - ChartMill","headline":"ARVN Stock Price, Quote & Chart | ARVINAS INC (NASDAQ:ARVN)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE9NT3dRSmhwT3lNVmx3SmFDN3REVVRpbnRhcTVoZ1Y1dVVMOTNYbDEtOGhfbXpZN2oycXBUNWprY3hRZTVxTlBxMVlxWmJfOXhvcU5iQ245QUJFVnJWcXfSAWNBVV95cUxOb3h3aDluQnc0SGRiMXdCc24zb191aXlwWlV5RXExdFRNWVNOdjFRelF0TjFxZ2JiMF9OM0NUakNva3hHbmp0Q0x4SlRkdTQzeU9yR2FLVWh1MV9EYzVvSW96UGc?oc=5","date":"2026-04-01","type":"pipeline","source":"Bitget","summary":"Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained? - Bitget","headline":"Arvinas (ARVN) Rises 6.9%: Can This Momentum Be Sustained?","sentiment":"neutral"},{"date":"2026-03-18","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPNGpWV0p4eFdxSElMZ0s4TERSczBaMFJTYjhmTm8wcEhDN29pNG1BeHBxTC1SSjdsUWNFdUJZWklIeGx1am9fcV9FYi1vbEdZX1F4a2dZSkZQRHZ4UUZ1YWNHNXJ2UVRndVEwY3N3SkpEWVRrdHpfWEp0U0o1Y2RfOV9hRHV5eUZMZHZYeWtYYzlCVWh3Y01WalQ0UVRON3VFT293eGxVbXpmaEFLOFZnWGszMm4xR3gtQjRUVHFLSQ?oc=5","date":"2026-02-12","type":"trial","source":"Stock Titan","summary":"Biotech behind first PROTAC trial taps dealmaker Randy Teel as CEO - Stock Titan","headline":"Biotech behind first PROTAC trial taps dealmaker Randy Teel as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxNYjF5N2lVbjNNdlgxT2R3ZzZ1SVBlMnpyX1pnZUswLUVMRGRZMEt4Y0NJS2ZJX3dRRmZXSW9mMGp2UzljczN6UEdxQ0NGYTR2bVYydkQ5SzVxLUtfNmFhWG9vQlhER2ZDRXYyaHJZZFdTQmtZZWpSdGdOc3dtYVdyMUh1d2UydFB2WkdQeG5oeDZrb1ZEb0hOLWdacVZfeDZjbmE1OW1pMkp0OU13M05abHVfUUI5SmZJdV9uaTNwV2RCeURoSk1ScU5UVU9JZVZFWnlNUFc2ekJHN3ZaaHZFZlF5a21iZ3RyYkE2bTVwVmZIVGZPUDNZYUVvang?oc=5","date":"2026-02-11","type":"regulatory","source":"The Malaysian Reserve","summary":"PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight - The Malaysian Reserve","headline":"PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | Delv","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-27","type":"pipeline","source":"simplywall.st","summary":"Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth - simplywall.st","headline":"Companies Like Arvinas (NASDAQ:ARVN) Are In A Position To Invest In Growth","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-18","type":"pipeline","source":"simplywall.st","summary":"Possible Bearish Signals With Arvinas Insiders Disposing Stock - simplywall.st","headline":"Possible Bearish Signals With Arvinas Insiders Disposing Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxPVGJjeGhMbndlVnNVNk5IVm5TUXFQUHFzT0FIUTBjSGRvakJ2VWFmUHJ3M3hONTFwTWNJNHl2UldMU2dBZmhXbEZvZEhiRTgtSnVnYkdkNWZOTDF0RFVDTVNiM0czX0NrUzZzYWM3UUxUc1M5dFR3TW02R3NXOWkzY2VqVDlNLUZVdWQ1ajdTYXpBc3ZzbWlUMUFwTTNTblNCWF9odGt6ejNEemdUOFlKdnR0eVJaMUcyLUZKbWlDXzgyOWZrS0pnbUxrcm91NFAwSldsbFEtTldlaUhTNnhfSlR3?oc=5","date":"2025-09-17","type":"pipeline","source":"Reuters","summary":"Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party - Reuters","headline":"Arvinas, Pfizer to grant commercial rights of experimental breast cancer drug to third party","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE03QTdKdGhOTjV5MFV0VG01bW5meVpjTkUxQzhhbllCUnFqX3FyUURka0FkZWU0akhLeTJ5WjdYNmt3UkZ4VFJkNXpSbWwxOXM2QU13RkV6aXVBNVo2UXhNMnNlOERDaXE1Ty13eC1yYnExOVhQeFQ5d3R5Qmw?oc=5","date":"2025-07-24","type":"pipeline","source":"Yahoo Finance","summary":"Arvinas, Inc. (ARVN): A Bull Case Theory - Yahoo Finance","headline":"Arvinas, Inc. (ARVN): A Bull Case Theory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNdkx2RGdUaURyTXE3ZFhYWDZkT29RazhXX2p6c21vWDNKNHAwWGFVRV94UGtaVFVfQzN1WlB5VzdQbUpPeTJBekJVMXRwdW85NHNmUUpwRmhVX1pGX25ud0t0WVdKaU9USzE4MHJqNFozcFBoRDFlX2ZBTXY1bW5KVzNXM0FIbGV6Sy1LV2RCb2dtSks5TVZn?oc=5","date":"2025-07-09","type":"pipeline","source":"citybiz","summary":"Arvinas Announces Retirement of CEO John Houston, Ph.D., - citybiz","headline":"Arvinas Announces Retirement of CEO John Houston, Ph.D.,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOZDVCXzIwQWJrbzFudXllUk9vNEhMLUxQaEhCbVNmSmFGZWZYZVlNTFJpVDNHUlFSVl9Kd1JxZHV5NXdMdlNJMjNXSzZ1NFQ3U2hETnVQbnRQdVkxSUZxQ2MzM0Nsc2FTLS1ma084Qkl2UkVoMDFYSjMyRXdhWDZneWpFdk9hMUtLcGY1Z0xNcERPUmxtcVNIajlQbUc4UTNKelhxWjlmX1pUMDZUdGhJN01KWk5Jdk56Y0xHa1dUQ2VVbGg2eUZ0SHBjQWdpRElRb21rUXZwTjdveUFl?oc=5","date":"2025-05-31","type":"pipeline","source":"Reuters","summary":"Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression - Reuters","headline":"Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQS1VPUFkyVlFLaGdKZTZRQjhNTXVZcXpXaHdXYnNsU0dPMjlNZGVqaUREQ09YcHhDakdYYUtQbmFfckpweDg0OVFnajEzUW55RC0tWXdDR1hveVVjSFNIa3l0c2FyMGxxY2ZMNFZEakJibmFQdzJTcVJ4U2VaZEpyZ0JCVjNKOHZDOGxLcS16T2drLXN5RHJoRlNYUTVuQnNu?oc=5","date":"2025-03-11","type":"deal","source":"Investor's Business Daily","summary":"Why Pfizer's Cancer Partner Just Plummeted More Than 50% - Investor's Business Daily","headline":"Why Pfizer's Cancer Partner Just Plummeted More Than 50% - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxPaE9qY3F4VEdfSmd0dUtuU2Y2cHVtdWUyNTRlUDQ5akpsakdxQ2t0Q25rd3pvczVNNEtlZ2E3WVJKS04tS0RwZU9TTE95OUc3dTFEYVpwZU5GM21qVXdKOHlvb2FXSllRenEyWjR3cTF5eVJDQXltWER0dFdkQzhnd3RIRUJmb3AtalAtcWJsNXc5ZFFMblZCeTlpNkNsOUhLbmJPV3FHN0Q5bERLR1QwWHFwM1kzTEFlTjZ1LW5HZzlkdXg4cThoVFJOb0xfWC03TUpvb3NSTXlkalRzSGdDZVNkUTBTRExwR05JeWFDcl9SQWwx?oc=5","date":"2025-03-11","type":"trial","source":"GlobeNewswire","summary":"Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial - GlobeNewswire","headline":"Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial","sentiment":"positive"}],"patents":[{"drugName":"ARV-110","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"ARV-471","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":4,"phaseCounts":{"phase_1":4},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Bayer","Pfizer","Gilead Sciences"],"therapeuticFocus":["Oncology","Protein Degradation"],"financials":{"source":"sec_edgar","revenue":262600000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":262600000,"period":"2025-12-31"},{"value":263400000,"period":"2024-12-31"},{"value":263400000,"period":"2024-12-31"},{"value":78500000,"period":"2023-12-31"},{"value":78500000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":285200000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-80800000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":717900000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":11.2,"previousClose":11.37,"fiftyTwoWeekHigh":14.51,"fiftyTwoWeekLow":5.9,"fiftyTwoWeekRange":"5.9 - 14.51","fiftyDayAverage":12.39,"twoHundredDayAverage":10.17,"beta":1.98,"enterpriseValue":50736536,"forwardPE":-3.2,"priceToBook":1.64,"priceToSales":2.74,"enterpriseToRevenue":0.19,"enterpriseToEbitda":-0.45,"pegRatio":0,"ebitda":-111900000,"ebitdaMargin":-42.6,"freeCashflow":-89012496,"operatingCashflow":-273800000,"totalDebt":8900000,"debtToEquity":2.1,"currentRatio":4.92,"returnOnAssets":-7.9,"returnOnEquity":-16.2,"analystRating":"2.2 - Buy","recommendationKey":"buy","numberOfAnalysts":16,"targetMeanPrice":14.88,"targetHighPrice":21,"targetLowPrice":6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":8.2,"institutionHeldPercent":86.6,"sharesOutstanding":63960997,"floatShares":55355045,"sharesShort":4786465,"shortRatio":5.63,"shortPercentOfFloat":7.5,"epsTrailing":-1.16,"epsForward":-3.52,"revenuePerShare":3.7,"bookValue":6.83,"officers":[{"age":45,"name":"Dr. Randy  Teel Ph.D.","title":"CEO, President & Director"},{"age":56,"name":"Mr. Andrew R. Saik","title":"CFO & Treasurer"},{"age":57,"name":"Ms. Angela M. Cacace Ph.D.","title":"Chief Scientific Officer"},{"age":61,"name":"Dr. Noah  Berkowitz M.D., Ph.D.","title":"Chief Medical Officer"},{"age":51,"name":"Mr. David K. Loomis M.B.A.","title":"VP & Chief Accounting Officer"},{"age":null,"name":"Mr. Jeff  Boyle","title":"Vice President of Investor Relations"},{"age":56,"name":"Mr. Jared M. Freedberg J.D.","title":"General Counsel & Corporate Secretary"},{"age":55,"name":"Mr. Steve  Weiss","title":"Senior VP & Chief Human Resources Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.arvinas.com","phone":"203 535 1456"}}